Renal Effects of Omapatrilat and Captopril in Salt-Loaded, Nitric Oxide-Deficient Rats

Hypertension

Volumn 42, Issue 5, 2003, Pages 937-944

  Ying, Lu ^b   Flamant, Martin ^b   Vandermeersch, Sophie ^b   Boffa, Jean Jacques ^b   Chatziantoniou, Christos ^b   Dussaule, Jean Claude ^a   Chansel, Dominique ^a,b  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Angiotensin converting enzyme; Hypertension, renal; Kidney failure; Nitric oxide; Peptides; Sodium, dietary

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OMAPATRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; RISK BENEFIT ANALYSIS; SALT INTAKE; SALT LOADING; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; CAPTOPRIL; CYCLIC GMP; ENDOTHELIN-1; ENZYME INHIBITORS; FIBROSIS; HYPERTENSION, RENAL; KIDNEY; MALE; NEPRILYSIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; SURVIVAL RATE; THIAZEPINES;

EID: 0242693934     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000099240.89890.94     Document Type: Article

References (42)

1. Fournie-Zaluski MC, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel JB, Roques BP. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem. 1994;37:1070-1083.
2. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17:S37-S43.
3. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis. 2000;35:179-188.
4. d'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue ET-1 increase: role of blood pressure and endothelial function. Hypertension. 1998;31:1305-1310.
5. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rats produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-281.
6. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension. 1992;20:298-303.
7. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice: role of endothelin. J Clin Invest. 1998;101:2780-2789.
8. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation. 1999;99:2185-2191.
9. Michel JB, Xu Y, Blot S, Philippe M, Chatellier G. Improved survival in rats administered L-NAME due to converting enzyme inhibition. J Cardiovasc Pharmacol. 1996;28:142-148.
10. Boffa JJ, Ying L, Dussaule JC, Chatziantoniou C. Improvements of renal lesions and function by angiotensin and endothelin receptor antagonism in nitric oxide deficient rats. JRAAS. 2001;2(suppl 1):S211-S216.
11. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension. 1996;27:1165-1172.
12. Arcos MI, Fujihara CK, Sesso A, de Almeida Prado EB, de Almeida Prado MJ, de Nucci G, Zatz R. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol. 2000;279: F1060-F1066.
13. Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995;275:745-752.
14. Backlund T, Palojoki E, Gronholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res. 2001;44:411-418.
15. Quasching T, d'Uscio LV, Shaw S, Grone HJ, Ruschitzka F, Luscher TF. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol. 2001;12:2280-2287.
16. Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol. 2002;283:R243-R248.
17. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease. Circulation. 2001;104:1856-1862.
18. Chen HH, Cataliotti A, Burnett JC Jr. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep. 2001;3(suppl 2):S15-S21.
19. Kubota E, Dean RG, Hubner RA, Balding LC, Johnston CI, Burrell LM. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. Curr Hypertens Rep. 2001; 3(suppl 2):S31-S33.
20. Quaschning T, Ruschitzka F, Luscher TF. Vasopeptidase inhibition: effective blood pressure control for vascular protection. Curr Hypertens Rep. 2002;4:78-84.
21. Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001;12:2051-2059.
22. Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl. 1997;15:S13-S19.
23. Baylis C, Harvey J, Engels K. Acute nitric oxide blockade amplifies the renal vasoconstrictor actions of angiotensin II. J Am Soc Nephrol. 1994; 5:211-214.
24. Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant. 2001:16(suppl 1):22-26.
25. Farina NK, Johnston CI, Burrell LM. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000;18:749-755.
26. Pu Q, Schiffrin EL. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2001;14:1067-1072.
27. Morazo P, Fortepiani LA, Clara Ortiz M, Atucha NM, Garcia-Estan J. Omapatrilat normalizes renal function curve in spontaneously hypertensive rats. BMC Pharmacol. 2001;1:5.
28. Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, Liao WC, Ruddy MC, Grim CE. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002;15:557-564.
29. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int. 2002;62:1349-1357.
30. Chansel D, Pham P, Nivez MP, Ardaillou R. Characterization of atrial natriuretic factor receptors in human glomerular epithelial and mesangial cells. Am J Physiol. 1990;259:F619-F627.
31. Chodjania Y, Tharaux PL, Ragueneau I, Dussaule JC, Picker JL, Funck-Brentano C, Jaillon P. Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia. Clin Pharmacol Ther. 2002;71: 468-478.
32. Sagnella GA, Saggar-Malik AK, Buckley MG, Markandu ND, Eastwood JB, MacGregor GA. Association between atrial natriuretic peptide and cyclic GMP in hypertension and in chronic renal failure. Clin Chim Acta. 1998;275:9-18.
33. Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics. 2000;3:45-58.
34. Fujihara CK, Michellazzo SM, de Nucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol. 1994;266:F697-F705.
35. Ardaillou R, Dussaule JC, Michel C, Chansel D, Ardaillou N, Kanfer A, Grimaldi A, Mignon F. Renal effects of atrial natriuretic factor and control of its secretion in various diseases. Adv Nephrol Necker Hosp. 1990;19:145-168.
36. Dussaule JC, Boffa JJ, Tharaux PL, Fakhouri F, Ardaillou R, Chatziantoniou C. Endothelin, renal diseases, and hypertension. Adv Nephrol Necker Hosp. 2000;30:281-303.
37. Schiffrin EL. Endothelin: role in experimental hypertension. J Cardiovasc Pharmacol. 2000;35(suppl 2):S33-S35.
38. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87-146.
39. Abassi ZA, Tate JE, Golomb E, Keiser H. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension. 1992;20:89-95.
40. Tharaux PL, Stefanski A, Ledoux S, Soleilhac JM, Ardaillou R, Dussaule JC. EGF and TGF-β regulate neutral endopeptidase expression in renal vascular smooth muscle cells. Am J Physiol. 1997;272(pt 1):C1836-C1843.
41. Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol. 1998;32:87-95.
42. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001;60:715-721.